[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634749":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":10,"responsibleParty":31,"collaborators":10,"id":33,"slug":10,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":52,"overallStatus":59,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":10},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"Inclisiran Cohort",null,"Patients receiving inclisiran injection(s).",{"label":13,"type":10,"description":14,"interventionNames":10},"Evolocumab Cohort","Patients receiving evolocumab injection(s).",{"label":16,"type":10,"description":17,"interventionNames":10},"Alirocumab Cohort","Patients receiving alirocumab injection(s).",{"label":19,"type":10,"description":20,"interventionNames":10},"Pooled Anti-PCSK9-mAb Cohort","Patients receiving anti-PCSK9-mAbs either evolocumab or alirocumab.",[22],{"name":23,"affiliation":23,"role":24},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":23,"role":27,"phone":10,"phoneExt":10,"email":10},{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100634749",false,"NCT07543731","A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab","Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy","VICTORION-LEAP","Inclusion criteria:\n\n* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.\n* Age ≥18 years at index date.\n* With at least 12 months data availability prior to index date.\n\nExclusion criteria:\n\n• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.","ALL","18 Years","99 Years",{"count":44,"type":45},5995,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.",[49,50,51],"Cardiovascular Diseases","Atherosclerotic Cardiovascular Disease","Hypercholesterolemia, Familial",[53,54,55,56,57,58],"Real-world","Retrospective","Adherence","Persistence","Long-term","PCSK9i","NOT_YET_RECRUITING","2026-04-14",{"date":62,"type":63},"2026-04-22","ACTUAL",{"date":65,"type":45},"2026-04-21",{"date":67,"type":45},"2026-09-30",{"name":23,"class":6}]